Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens

AIDS

Volumn 15, Issue 1, 2001, Pages 61-69

  Montaner, Julio S G ^a,b,c   Harrigan, P Richard ^a   Jahnke, Natalie ^a   Raboud, Janet ^b,c   Castillo, Eliana ^a   Hogg, Robert S ^a,b   Yip, Benita ^a   Harris, Marianne ^a   Montessori, Val ^a,b   O'Shaughnessy, Michael V ^a,b,c  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Canadian HIV Trials Network   (Canada)

Author keywords

AIDS; Antiretroviral therapy; HIV; HIV drug resistance; Multiple drug rescue therapy

Indexed keywords

ABACAVIR; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CONSUMER PRODUCT SAFETY; DRUG RESISTANCE, MICROBIAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 0035808534     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200101050-00010     Document Type: Article

References (24)

1. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: Lessons from the implementation of viral load-driven antiretroviral therapy
2. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
5. Improved survival among HIV infected individuals following initiation of triple combination antiretroviral regimens
6. Antiretroviral treatment in 1998
7. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society-USA Panel
8. HIV-1: Rambling on the evolution of drug resistance?
9. Clinical failure is associated with highly mutated RT and protease
10. Baseline resistance profile predicts response to ritonavir/saquinavir therapy in a community setting
11. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
12. Longitudinal data analyses using generalized linear models
13. Virological and immunological response to mega-HAART salvage therapy after failure of multiple antiretroviral regimens
14. Surrogate marker responses to multidrug combinations comprising hydroxyurea, efavirenz, double protease inhibitors and nucleoside analogues in protease inhibitor failures
15. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV Trials Network Protocol 080
16. Phase I/II dosing study of once-daily hydroxyurea (HU) alone vs didanosine (ddl) alone vs ddl+HU
17. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
18. Impact of moderate decreases in baseline NNRTI susceptibility on response to antiretroviral therapy
19. Mechanisms of virologic failure in previously untreated hiv-infected patients from a trial of induction-maintenance therapy
20. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy
21. Prevalence of resistance-associated genotypic mutations in plasma HIV of patients failing triple therapy combination
22. Salvage therapy with abacavir, amprenavir and efavirenz in subjects with plasma HIV-I RNA >500 copies/mL despite protease inhibitor therapy
23. Novel four-drugs treatment regimens after failure of a human inmmunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
24. Factors associated with the successful modification of antiretroviral therapy